Clinical Trial Update: Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating botulinum toxin for spastic lower limb paresis in patients with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Botulinum toxin (botulinum toxin)

Snippet

Sponsor: Aránzazu Vázquez Doce | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED